DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Novartis
National Institutes of Health Clinical Center (CC)
Yale University
NRG Oncology
University of Florida
Duke University
Cambridge University Hospitals NHS Foundation Trust
Yale University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Merck Sharp & Dohme LLC
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)